Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ChemTrak/Whitehall Labs

This article was originally published in The Gray Sheet

Executive Summary

Cancel U.S. marketing agreement for the O-T-C version of ChemTrak's AccuMeter total cholesterol test, cleared by FDA on March 2 ("The Gray Sheet" March 8, p. 14). The December 1991 agreement was terminated by Whitehall Labs parent American Home Products, effective Oct. 23, due to a "change in corporate priorities." ChemTrak markets the same test in the U.S. for professional use through distributors. The Sunnyvale, California firm currently is evaluating other potential U.S. partners and the possibility for direct sales in niche U.S. markets.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT001286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel